| Jiaheng Li,Mei Jiang,Xiaoting Zhao,Ziyu Wang,Meng Gu,Weiying Li. Cisplatin selects for CD133+ cells in lung cancer cells. Oncol Transl Med, 2020, 6: 16-20. |
| 肺癌细胞中顺铂对CD133+细胞进行富集 |
| Cisplatin selects for CD133+ cells in lung cancer cells |
| Received:May 06, 2019 Revised:June 10, 2019 |
| DOI：10.1007/s10330-019-0355-5 |
| 中文关键词: CD133；顺铂；肺癌细胞 |
| 英文关键词: CD133;Cisplatin;Lung cancer cells |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Jiaheng Li | Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute | ljhhbmu@126.com | | Mei Jiang | Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Xiaoting Zhao | Department of Cellular Molecular Biology,Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Ziyu Wang | Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Meng Gu | Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Weiying Li* | Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute | li_weiying412@aliyun.com |
|
| Hits: 9229 |
| Download times: 11952 |
| 中文摘要: |
| 基于铂的化疗是非小细胞肺癌的一线治疗，但大多数患者都会复发。最近的证据表明CD133+细胞是耐药性和肿瘤复发的原因。然而顺铂和CD133+细胞之间的相关性尚未进行系统的研究。在这项研究中，我们使用五种肺癌细胞系来研究顺铂和CD133+细胞之间的相关性。结果显示顺铂可以富集CD133+细胞，这种富集显示出时间和剂量的相关性。随着治疗时间和剂量的增加，CD133+细胞的比例将增加。去除顺铂后随着孵育时间的延长，富集将减弱，但CD133+细胞的比例仍然高于基础水平。与贴壁培养相比，悬浮培养细胞后CD133+细胞的比例增加。当顺铂处理和悬浮培养共存时，CD133+细胞的比例显著增加。这些结果表明，顺铂诱导了CD133+细胞富集，CD133是一种新的治疗靶点。 |
| 英文摘要: |
| Objective Platinum-based chemotherapy is the first-line treatment for non–small cell lung cancer, but the
chemoresistance of tumor cells continues to be a considerable challenge in the management of NSCLCs,
leading to recurrence of most patients. CD133 (prominin-1) is a five-transmembrane glycoprotein, and
recent evidence suggests that CD133+ cells are the cause of drug resistance and tumor recurrence. In this
study, the correlation between cisplatin and CD133+ cells was investigated systematically.
Methods Four lung cancer cell lines, including A549, H460, 801D and H1299, were treated with different
concentrations of cisplatin. Cell viability was determined by MTT assay. Sphere-forming assay was
performed to detect the capability of sphere-forming. CD133+ cells was detected by BD FACScaliber flow
cytometer.
Results The results showed that cisplatin could increase the number of CD133+ cells in both time- and
dose-dependent manner. The enrichment would weaken but the proportion of CD133+ cells was still higher
than the basic level as incubation time extended after cisplatin was withdrawn. Compared with adherent
culture, the proportion of CD133+ cells was higher when the cells were maintained suspension culture.
The proportion of CD133+ cells significantly increased when cisplatin was provided in suspension culture.
Conclusion These results revealed that cisplatin induces the enrichment of CD133+ cells and CD133
is a new therapeutic target. Our data partially explained drug resistance to second-line chemotherapy in
cisplatin-treated patients with NSCLCs. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|